IBT-B.ST

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$732M	—	$-6.72	$-6.72–$-6.72	—	1
2027	$176M	-76.0%	$24.65	$24.65–$24.65	—	1
2028	$382M	+116.9%	$-1.66	$-1.66–$-1.66	—	1
2029	$666M	+74.6%	$6.23	$6.23–$6.23	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 1 of the last 3 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-26	$-1.54	$-2.18	-41.7%
2026-05-06	$-1.41	$-1.70	-20.6%
2026-02-06	$-1.43	$-1.43	+0.0%

DCF fair valuemodel estimate

Intrinsic value

$8.30

Price

$65.90

Implied downside

-87%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
IBT-B.STInfant Bacterial Therapeutics AB (publ)	$65.90	-0.15%	$858M	—
ADDV-B.STADDvise Group AB (publ)	$1.73	+0.58%	$1.0B	—
CANTA.STCantargia AB (publ)	$1.56	-1.27%	$440M	—
CLBIO.STCorline Biomedical AB	$15.15	-0.33%	$396M	—
GUARD.STGuard Therapeutics International AB (publ)

Infant Bacterial Therapeutics AB (publ)

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.

www.ibtherapeutics.com

Employees: 6
IPO / List date: Mar 29, 2016
HQ: SE

Held by traders on TradeandTell

No one on the platform currently holds IBT-B.ST.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in IBT-B.ST as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded IBT-B.ST yet.